The Latest Analyst Ratings for Ascendis Pharma
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 13 analysts have published their opinion on Ascendis Pharma (NASDAQ:ASND) stock. The company has an average price target of $119.38, a decrease of 1.34% from the previous average price target of $121.00. The majority of analysts are indifferent about the stock, with 10 out of 13 giving it a neutral rating.
September 07, 2023 | 4:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Ascendis Pharma has received mostly neutral ratings from analysts, with a decreased average price target.
The majority of analysts are indifferent about Ascendis Pharma, indicating uncertainty about the stock's future performance. The decrease in the average price target could potentially impact the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100